The application of IL-6 blockers as anti-cancer agents has been investigated in many cancer types, but the only currently approved monoclonal antibodies (mAbs) in the United States are tocilizumab (anti-IL-6Rα) and siltuximab (anti-IL-6). The gene discussed is IL6; the disease is cancer.